Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe
- Autores: Asboe D, Bansi L, Camacho R, Codoñer FM, De Luca A, Di Giambenedetto S, Dunn D, Fanti I, Ghisetti V, Kaiser R, Prosperi MCF, Sönnerborg A, Torti C, van de Vijver DC, Van Laethem K, Vandamme AM, Zazzi M
- Ano de Publicação: 2013
- Journal: Journal of Infectious Diseases
- Link: http://jid.oxfordjournals.org/content/early/2013/01/11/infdis.jit017.abstract
HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20,323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis.